NIH begins large clinical trial to test immune modulators for treatment of COVID-19

16-Oct-2020 12:40 PM EDT, by NIH/Office of the Director

Newswise — The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation -- called a "cytokine storm" -- that can lead to acute respiratory distress syndrome, multiple organ failure and other life-threatening complications. The clinical trial aims to determine if modulating that immune response can reduce the need for ventilators and shorten hospital stays. The trial, known as ACTIV-1 Immune Modulators (IM), will determine if the therapeutics are able to restore balance to an overactive immune system.

Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, the trial expects to enroll approximately 2,100 hospitalized adults with moderate to severe COVID-19 at medical facilities in the United States and Latin America. The National Center for Advancing Translational Sciences (NCATS), part of NIH, will coordinate and oversee the trial with funding support from the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response, in support of the Trump administration's Operation Warp Speed goals. BARDA's Clinical Studies Network will be responsible for operationalizing the trial through a task order awarded to contract research organization Technical Resources International, Inc.

"This is the fifth master protocol to be launched under the ACTIV partnership in an unprecedented timeframe, and focuses efforts on therapies that hold the greatest promise for treating COVID-19," said NIH Director Francis S. Collins, M.D., Ph.D. "Immune modulators provide another treatment modality in the ACTIV therapeutic toolkit to help manage the complex, multi-system conditions that can be caused by this very serious disease."

ACTIV-1 IM is a randomized, placebo-controlled trial that uses an adaptive master protocol. One of the hallmarks of master protocols is that they allow coordinated and efficient evaluation of multiple investigational agents as they become available. This enables maximum flexibility to swiftly weed out drugs that do not demonstrate effectiveness, identify those that do in a short time frame, and rapidly incorporate additional experimental agents into the trial.

The ACTIV public-private partnership selected three agents for the study from a pool of over 130 immune modulators initially reviewed based on several factors, including their relevance to COVID-19, strong evidence for use against inflammatory reaction and cytokine storm, and availability for large-scale clinical studies. The initial agents are infliximab (REMICADE), developed by Janssen Research & Development, LLC., one of the Janssen Pharmaceutical Companies of Johnson & Johnson; abatacept (ORENCIA), developed by Bristol Myers Squibb; and Cenicriviroc (CVC), an investigational late-stage agent developed by AbbVie.

All participants in the trial will receive remdesivir, which is the current standard of care treatment of hospitalized patients with COVID-19. Convalescent plasma and dexamethasone will be allowed at the discretion of the site investigator and in accordance with national guidelines. They will be randomly assigned to receive a placebo or one of the immune modulators as an add-on treatment. The trial will study the different combination treatment regimens with respect to illness severity, recovery speed, mortality and hospital resource utilization.

Enrollment is now open, and the trial is expected to last approximately six months. Results will be available shortly after the trial is completed, or possibly sooner if analysis conducted during the trial indicates that one or more of the drugs is beneficial. To ensure that the trial is being conducted in a safe and effective manner, an independent data and safety monitoring board will oversee the trial and conduct periodic reviews of the accumulating data.

The protocol team chair is William G. Powderly, M.D., director of the Institute for Clinical and Translational Sciences and co-director of the Division of Infectious Diseases at Washington University School of Medicine in St. Louis. NCATS' Clinical and Translational Science Awards (CTSA) Program and the Trial Innovation Network will play a key role in adding U.S. study sites and enrolling patients, including those from communities disproportionately affected by COVID-19.

"The CTSA Program's nimbleness and innovation in conducting clinical trials--along with the network's extensive capacity and broad geographical reach--have positioned it to rapidly implement this important trial," said NCATS Director Christopher P. Austin, M.D. "The innovative trial design will allow efficient evaluation of three different potential COVID-19 treatments concurrently, delivering new possible treatments for patients more quickly and valuable insights into the science of clinical translation."

###

 

NIH announced the ACTIV initiative in April 2020 to develop a national research response to prioritize and speed the development of the most promising COVID-19 treatments and vaccines. Coordinated by the Foundation for the National Institutes of Health, ACTIV brings together partners from government, industry, academia and non-profit organizations.
Visit the ACTIV Therapeutics page.

About HHS, ASPR, and BARDA:

HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures - vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. To date, 55 BARDA-supported products have achieved FDA approval, licensure or clearance. For more on BARDA's development portfolios and on partnering with BARDA, visit medicalcountermeasures.gov. To learn more about federal public health and medical preparedness and response, visit phe.gov.

About the National Center for Advancing Translational Sciences (NCATS):

NCATS conducts and supports research on the science and operation of translation--the process by which interventions to improve health are developed and implemented--to allow more treatments to get to more patients more quickly. For more information about how NCATS helps shorten the journey from scientific observation to clinical intervention, visit https://ncats.nih.gov.

About the National Institutes of Health (NIH):

NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov.

NIH...Turning Discovery Into Health®




Filters close

Showing results

110 of 3718
Released: 20-Oct-2020 5:40 PM EDT
Nearly a Quarter of New York City Transit Workers Report Having Had COVID-19
New York University

A survey of New York City’s bus and subway workers finds that 24 percent report having contracted COVID-19 and 90 percent fear getting sick at work. The pilot study, conducted by researchers at NYU School of Global Public Health, in coordination with the Transport Workers Union (TWU) Local 100, helps document the toll the pandemic has taken on the physical and mental health of essential workers.

Released: 20-Oct-2020 5:10 PM EDT
Viral post claiming Dr. Anthony Fauci was indicted is entirely false
Newswise

A Facebook post from May that is newly gaining traction says that Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and the leading voice of experts in the coronavirus pandemic, has been indicted for treason. This claim is entirely false. Despite President Donald Trump calling him a "disaster," Fauci has not been indicted. There is no news coverage to support this claim, nor any original, credible documents or sources to corroborate it.

Released: 20-Oct-2020 4:10 PM EDT
Safety Considerations for Visiting Primary Care Doctors
Rutgers University-New Brunswick

The COVID-19 pandemic has left many people with chronic health conditions relying on telemedicine rather than seeing their doctor in person when necessary or putting off important visits entirely because they fear being infected. Ann M. Nguyen, an assistant research professor at Rutgers Center for State Health Policy at the Institute for Health, Health Care Policy and Aging Research, who recently published a paper on safety measures at physician offices, discusses what people should know about visiting their doctor and why putting off appointments that need to be done in person could lead to other health problems.

Released: 20-Oct-2020 3:50 PM EDT
New Jersey, Nation Surpass Halfway Employment Recovery Mark
Rutgers University-New Brunswick

New Jersey gained back half of the jobs lost due to the coronavirus pandemic but a wide disparity remains between higher-income professionals working at home and lower-wage support workers still bearing the brunt of the economic downturn that has gripped the nation, according to a new Rutgers report.

Newswise: 246364_web.jpg
Released: 20-Oct-2020 3:25 PM EDT
Effective ventilation may be a key factor in preventing the spread of COVID-19
ESTONIAN RESEARCH COUNCIL

During the first wave of COVID-19, which paralyzed the world in spring, it was initially thought that effective hand washing and 2-metre social distancing would help prevent the highly contagious virus.

Released: 20-Oct-2020 3:10 PM EDT
Researchers discovered the second 'key' used by the SARS-CoV-2 virus to enter into huma
University of Helsinki

To efficiently infect human cells, SARS-CoV-2, the virus that causes COVID-19, is able to use a receptor called Neuropilin-1, which is very abundant in many human tissues including the respiratory tract, blood vessels and neurons. The breakthrough discovery was made by a German-Finnish team of researchers led by neuroscientists Mika Simons ,Technical University of Munich, Germany and virologist Giuseppe Balistreri, University of Helsinki, Finland.

Released: 20-Oct-2020 2:50 PM EDT
Population currently sees coronavirus as the greatest health risk
BFR Federal Institute For Risk Assessment

Next on the list of concerns, though notably less frequently mentioned, are unhealthy or wrong diet as well as climate and environmental pollution - these were the most frequently mentioned concerns in February's survey. "The coronavirus pandemic dominates public perception", says BfR President Professor Dr. Dr. Andreas Hensel.

Released: 20-Oct-2020 2:45 PM EDT
Trump Mocked Biden for Saying He'll ‘Listen to the Scientists’
Newswise

U.S. President Donald Trump emphasized his stark contrast to his opponent Joe Biden in dealing with the COVID-19 pandemic when he mocked Biden for saying he'll "listen to scientists."

Released: 20-Oct-2020 2:35 PM EDT
Most psoriasis patients taking immunosuppressants survive COVID-19
National Institute for Health Research

Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19. According to the first findings from a global registry of psoriasis and COVID-19 patients, led by Guy's and St Thomas' clinicians, over 90% survive.

Newswise: Halloween Safety in the Coronavirus Era
Released: 20-Oct-2020 2:20 PM EDT
Halloween Safety in the Coronavirus Era
Cedars-Sinai

Halloween isn't going to be the same this year, but families can still have fun while reducing their risk of exposure to the virus that causes COVID-19 (coronavirus), says Priya Soni, MD, a Cedars-Sinai pediatric infectious disease specialist.


Showing results

110 of 3718

close
1.1134